LCMS Bioanalysis of Antibody Drugs Using Fab-Selective Proteolysis nSMOL - Part 2 - Bevacizumab analysis -

nSMOL is Shimadzu's completely new and breakthrough technology that enables selective proteolysis of the Fab region of monoclonal antibodies. This technique facilitates method development independent of a variety of antibody drugs and achieves a paradigm shift in the bioanalysis of antibody drugs.
Furthermore, this is the only method with respect to antibody drugs that has fulfilled the criteria of "Guideline on Bioanalytical Method Validation in Pharmaceutical Development" for low MW drug compounds issued by the Japanese Ministry of Health, Labour and Welfare. Shimadzu also offers optimization methods and protocols, and nSMOL can be applied to clinical research at various institutions.

Content Type:
Application
Document Number:
LAAN-A-LM-E117A
Product Type:
Liquid Chromatograph-Mass Spectrometry, Mass Spectrometry
Keywords:
nSMOL, LCMS Bioanalysis, Antibody drug, Fab-selective proteolysis, Bevacizumab, Pharmaceutical, Life Science, LCMS-8050, LCMS-8060, NexeraX2 System
Language:
English
File Name:
jpo117016.pdf
File Size:
621kb

Free Download

For Research Use Only. Not for use in diagnostic procedures.

This page may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

Top of This Page